Table 1 Patient demographics of group 1, group 2, and group 3

No

20

15

12

Gender, n (%)

0.590^a,0.022^b

 Male

15(75.0%)

10(66.7%)

12(100%)

 Female

5(25.0%)

5(33.3%)

0(0%)

Age, n (%)

0.486^a,0.197^b

 ≥60

7(35.0%)

7(46.7%)

7(58.3%)

 <60

13(65.0%)

8(53.3%)

5(41.7%)

Pathologic type, n (%)

1.000^a,0.360^b

 Clear cell

16(80.0%)

12(80.0%)

11(91.7%)

 Non-clear cell

4(20.0%)

3(20.0%)

1(8.3%)

Nuclear grade, n (%)

0.005^a,0.488^b

 G1 + G2

3(15.0)

9(60.0%)

3(25.0%)

 G3 + G4

17(85.0%)

6(40.0%)

9(75.0%)

VT level, n (%)

0.039^a,0.900^b

 Above hepatic vein

3(15.0%)

7(46.7%)

2(16.7%)

 Below hepatic vein

17(85.0%)

8(53.3%)

10(83.3%)

Tumor size, (cm ± SD)

9.9 ± 2.4

10.8 ± 4.0

9.8 ± 1.8

0.439^a,0.903^b

T stage, n (%)

0.726^a,1.000^b

 T3

15(75.0%)

12(80.0%)

9(75.0%)

 T4

5(25.0%)

3(20.0%)

3(25.0%)

N stage, n (%)

0.061^a,0.252^b

 N0

13(65.0%)

5(33.3%)

10(83.3%)

 N1

7(35.0%)

10(66.7%)

2(16.7%)

0.001^a,0.586^b

 1

18(90.0%)

6(40.0%)

10(83.3%)

 >1

2(10.0%)

9(60.0%)

2(16.7%)

ECOG PS

0.015^a,0.742^b

 0

16(75.0%)

6(40.0%)

9(75.0%)

 1

4(25.0%)

9(60.0%)

3(25.0%)